The Big News
In this last Update of 2020, we wish you a happy remainder of the holiday season and a fantastic new year. Thank you once again for reading, sharing, contributing and passionately advocating for recovery. Thanks, also, to colleagues throughout the Hazelden Betty Ford Foundation, who advocate every day for individuals, families and communities affected by addiction. Special gratitude to Samantha Moy-Gottfried, David Piluso, Daniel Johnson, Shari Nye, Elizabeth Drutschmann, Mindy Hansen, Cathy Hufford, Karen Olson and Laura Jendersee—whose efforts and expertise help make this Update possible.
Speaking of the holidays, our colleagues Heidi Wallace and Carrie Bates had a long, robust conversation about substance-related challenges during the holiday season on Straight Talk with Laural Porter, which aired over the weekend on Portland’s NBC affiliate KGW. It’s a great segment. Watch and share with others you know who may face challenges this time of year. Here, too, are some tips for protecting one’s recovery during the holidays.
Sticking with the holiday theme, a quick invitation to our Minnesota readers… please consider joining us at an exciting alcohol-free party we’re throwing in Minneapolis to ring in the new decade—Hazelden Betty Ford and Dissonance present Resolution 2020: A Zero Proof New Year’s Eve with HALEY, Lydia Liza and Moe Yaqub!
Now, on to other news …
Five months after Los Angeles Angels pitcher Tyler Skaggs died in a hotel room with two opioids in his bloodstream, Major League Baseball and its players’ union announced a new drug policy that adds opioid and cocaine testing for major leaguers and no longer punishes marijuana use in the major or minor leagues.
If we want to prevent addiction, it starts with pediatricians. That’s according to research in our new Emerging Drug Trends report, which makes the case for routine substance use screenings for adolescents.
As Purdue Pharma buckles under a mountain of litigation and public protest in the United States, its foreign affiliate, Mundipharma, has expanded, using some of the same tactics to sell the addictive opioids that made its owners, the Sackler family, a fortune. That’s according to a new report by The Associated Press, which says Mundipharma is also pushing another strategy globally: dominate the overdose-antidote market with its Nyxoid-branded naloxone nasal spray, which is similar to Narcan in the U.S.
Mental Health for US is holding a forum in New Hampshire tonight to draw awareness in the presidential campaign to both mental health and addiction issues. Watch the livestream on Facebook.
The FDA is chastising Alkermes for “misbranding” Vivitrol, one of the medications used to treat opioid addiction, and underselling its risks. It is unfortunate to hear of this issue related to a medication we use regularly. We have seen Vivitrol contribute to good outcomes in our system, where it’s combined with evidence-based psychosocial therapies and peer support. We are aware of the risks—as we are with all medications—and always communicate them clearly to our patients who consider them. Those
risks also need to be clear in direct-to-consumer marketing. We have found that people who self-select for the medication do best and, due to the concerns raised, we would not recommend people be coerced to take Vivitrol or any other medication. Our Professional Education Solutions team trains providers nationwide on all aspects of treating opioid use disorder, including the use of medications. Team leaders report that knowledge and understanding have improved greatly over the past couple of years, enabling physicians and patients to make better decisions around which medication to utilize for each individual person.
Finally, the U.S. Senate voted 72-18 to confirm Dr. Stephen Hahn as the new FDA commissioner, as the agency faces pressure to reduce teenage vaping and weighs competing interests on a long-delayed proposal to ban flavored e-cigarettes. Some have criticized Dr. Hahn for sidestepping questions on the vaping crisis during earlier
confirmation hearings. Meanwhile, former FDA chief Dr. Scott Gottlieb, who left the post in April, continues to weigh in, saying last week that products from Juul, the vaping company with the largest market share of e-cigarettes, “should be pulled off the market entirely.”
This week’s featured media is the latest episode in our award-winning Let’s Talk Addiction & Recovery podcast series, with host William C. Moyers talking to Christopher Yadron, Ph.D., about today’s most-effective addiction treatment approaches, including: specific treatment modalities for opioid, alcohol and meth addiction, important mental health considerations, group therapy and long-term recovery support. Watch, listen or read.
Share: Tweet | Facebook | LinkedIn
|